Paper41574478
Tumor-Selective and Chemical Activation Strategies for Nitrogen Mustard Prodrugs.
Ponnamperumage TNF and 7 others. Chemistry, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Tumor-Selective and Chemical Activation Strategies for Nitrogen Mustard Prodrugs. Papers, record 41574478. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41574478
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Prodrugs | Major topic |
| Neoplasms | Major topic |
| Mechlorethamine | Major topic |
| Nitrogen Mustard Compounds | Major topic |
| Humans | |
| Reactive Oxygen Species | |
| Hydrogen-Ion Concentration | |
| DNA | |
| Antineoplastic Agents | |
| Animals |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R15 CA277656 | NCI NIH HHS | United States | R15CA277656 | PubMed |
| 1R15CA277656-01 | NCI NIH HHS | United States | R15CA277656 | PubMed |
Source NIH RePORTER
References91
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17606726 | Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. | Clin Cancer Res | 2007 | https://conductscience.org/library/papers/17606726 | PubMed |
| 2 | 8356908 | Role of glutathione in cellular resistance to alkylating agents. | Adv Enzyme Regul | 1993 | https://conductscience.org/library/papers/8356908 | PubMed |
| 3 | 39757165 | Systematic and comprehensive insights into HIF-1 stabilization under normoxic conditions: implications for cellular adaptation and therapeutic strategies in cancer. | Cell Mol Biol Lett | 2025 | https://conductscience.org/library/papers/39757165 | PubMed |
| 4 | 21606941 | Targeting hypoxia in cancer therapy. | Nat Rev Cancer | 2011 | https://conductscience.org/library/papers/21606941 | PubMed |
| 5 | 7707327 | Hypoxia-selective antitumor agents. 11. Chlorambucil N-oxide: a reappraisal of its synthesis, stability, and selective toxicity for hypoxic cells. | J Med Chem | 1995 | https://conductscience.org/library/papers/7707327 | PubMed |
| 6 | 27992994 | A New Cross-Link for an Old Cross-Linking Drug: The Nitrogen Mustard Anticancer Agent Mechlorethamine Generates Cross-Links Derived from Abasic Sites in Addition to the Expected Drug-Bridged Cross-Links. | Biochemistry | 2016 | https://conductscience.org/library/papers/27992994 | PubMed |
| 7 | 17440684 | Hypoxia in cancer: significance and impact on clinical outcome. | Cancer Metastasis Rev | 2007 | https://conductscience.org/library/papers/17440684 | PubMed |
| 8 | 21833026 | Dysregulated pH: a perfect storm for cancer progression. | Nat Rev Cancer | 2011 | https://conductscience.org/library/papers/21833026 | PubMed |
| 9 | 39124883 | Recent Advances in the Application of Nitro(het)aromatic Compounds for Treating and/or Fluorescent Imaging of Tumor Hypoxia. | Molecules | 2024 | https://conductscience.org/library/papers/39124883 | PubMed |
| 10 | 26713684 | Preparation of Conjugated Polymer Grafted with H2O2-Sensitive Prodrug for Cell Imaging and Tumor Cell Killing. | ACS Appl Mater Interfaces | 2016 | https://conductscience.org/library/papers/26713684 | PubMed |
| 11 | 23845143 | Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia. | Chin J Cancer | 2014 | https://conductscience.org/library/papers/23845143 | PubMed |
| 12 | 8515422 | Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards. | J Med Chem | 1993 | https://conductscience.org/library/papers/8515422 | PubMed |
| 13 | 28140568 | DNA Adduct Profiles Predict in Vitro Cell Viability after Treatment with the Experimental Anticancer Prodrug PR104A. | Chem Res Toxicol | 2017 | https://conductscience.org/library/papers/28140568 | PubMed |
| 14 | 8691449 | Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. | J Med Chem | 1996 | https://conductscience.org/library/papers/8691449 | PubMed |
| 15 | 37492477 | Association between pH regulation of the tumor microenvironment and immunological state. | Front Oncol | 2023 | https://conductscience.org/library/papers/37492477 | PubMed |
| 16 | 30199705 | Structure-activity relationship study of hypoxia-activated prodrugs for proteoglycan-targeted chemotherapy in chondrosarcoma. | Eur J Med Chem | 2018 | https://conductscience.org/library/papers/30199705 | PubMed |
| 17 | 20222798 | Hypoxia-activated prodrugs in cancer therapy: progress to the clinic. | Future Oncol | 2010 | https://conductscience.org/library/papers/20222798 | PubMed |
| 18 | 26911188 | Antitumour actions of interferons: implications for cancer therapy. | Nat Rev Cancer | 2016 | https://conductscience.org/library/papers/26911188 | PubMed |
| 20 | 41550162 | Targeted drug conjugates in cancer therapy: Challenges and opportunities. | Pharm Sci Adv | 2024 | https://conductscience.org/library/papers/41550162 | PubMed |
| 21 | 8358728 | Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. | Cancer Res | 1993 | https://conductscience.org/library/papers/8358728 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42622024 | Unraveling the Crosstalk Between Ferroptosis and Cuproptosis for Rational Nanomedicine Design in Cancer. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42622024 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41574478
GET https://conductscience.org/api/papers/v1/41574478/references?page=2